Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett’s according to a selective management algorithm
Endoscopy International Open · 27.02.2026 · 14 (CP)
DOI: 10.1055/a-2778-3907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 27.02.2026. Verfasst von Tony He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, St Vincent's Hospital Melbourne Pty Ltd., Fitzroy, Australia. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Current European and American guidelines conflict in their recommendations for surveillance versus endoscopic therapy for low-grade dysplastic Barrett’s (LGD). We aimed to evaluate the performance of a selective management algorithm and provide real-world outcomes. Data on 497 patients with dysplastic Barrett’s were collected prospectively between 2008 and 2022 at a Barrett’s referral unit. LGD was defined as confirmation of LGD by an expert gastrointestinal pathologist. Persistent unifocal LGD or multifocal LGD were considered high-risk features for progression and patients underwent endoscopic eradication therapy (EET). Patients with non-persistent unifocal LGD were deemed low-risk and were surveilled. Primary outcome was progression rate to high grade dysplasia or neoplasia. A total of 135 patients had LGD (median [interquartile range] follow up: 4.8 years [1.0–7.1]): 22 patients met low-risk criteria and were surveilled (LR-S), eight patients met high-risk criteria and were surveilled (HR-S; patient preference n = 4, medical comorbidities n = 4), and 105 patients met high-risk criteria and underwent EET (HR-EET). Progression rates were similar between the LR-S and HR-EET cohorts (4.5% [n = 1/22] vs. 6.7% [n = 8/105]; P = 0.43). The HR-S group had a significantly higher progression rate (25% [n = 2/8]; P = 0.04). Univariable analysis showed reflux esophagitis (sub-distribution hazard ratio 3.21, 95% confidence interval 1.02–10.1, P = 0.04) was associated with progression risk in the high-risk LGD cohort only. This selective management algorithm for LGD is safe. Surveillance is appropriate in low-risk LGD patients. Patients with high-risk features who are surveilled and/or have reflux esophagitis may have an increased progression risk and should undergo EET with optimized acid suppression therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology, St Vincent's Hospital Melbourne Pty Ltd., Fitzroy, Australia.
- Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia.
- Statistics, Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia.
- Pathology, St Vincent's Hospital Melbourne Pty Ltd., Fitzroy, Australia.
- Center for Interventional Endoscopy, St Vincent's Hospital Melbourne Pty Ltd., Fitzroy, Australia.
- Medicine, Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia.
ORCID-Profile: Edward H Tsoi
Zitieren
APA
He, T., Lai, M., Iyer, K. G., Vogrin, S., Slavin, J. L., Tsoi, E. H., Holt, B., Desmond, P., & Taylor, A. C. (2026). Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett’s according to a selective management algorithm. Endoscopy International Open, 14(CP). https://doi.org/10.1055/a-2778-3907
Vancouver
He T, Lai M, Iyer KG, Vogrin S, Slavin JL, Tsoi EH, et al. Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett’s according to a selective management algorithm. Endoscopy International Open. 2026;14(CP). doi:10.1055/a-2778-3907
BibTeX
@article{He2026,
author = {He, Tony and Lai, Mark and Iyer, Kiran G and Vogrin, Sara and Slavin, John L and Tsoi, Edward H and Holt, Bronte and Desmond, Paul and Taylor, Andrew Cf},
title = {Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett’s according to a selective management algorithm},
journal = {Endoscopy International Open},
year = {2026},
volume = {14},
number = {CP},
doi = {10.1055/a-2778-3907}
}
EUVIMED